Interestingly, this retrospective study reported a more rapid cognitive decline in the group of PD-GBA1 treated with STN-DBS compared to non-GBA1 carriers treated with DBS, non-GBA1 carriers not treated with DBS and PD-GBA1 not treated with DBS. This evidence concerns the gene GBA1 and Parkinson disease.